
PD-1 / PD-L1
Se han encontrado 92 productos de "PD-1 / PD-L1"
Durvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Pureza:95% - 97.2% (SDS-PAGE); 95.3% (SEC-HPLC)Forma y color:LiquidPeso molecular:146.03 kDaBudigalimab
CAS:Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.
Pureza:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Forma y color:LiquidSpartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Pureza:SDS-PAGE:95.2%;SEC-HPLC:96.3%Forma y color:LiquidPeso molecular:145.74 kDaBMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFórmula:C35H35ClN2O7Pureza:97.36%Forma y color:SolidPeso molecular:631.11Ref: TM-T10565
1mg52,00€5mg120,00€10mg187,00€25mg380,00€50mg612,00€100mg973,00€200mg1.305,00€1mL*10mM (DMSO)169,00€Sintilimab
CAS:Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.
Pureza:> 95%Forma y color:LiquidPeso molecular:144.04 kDaAUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFórmula:C144H230N40O50Pureza:95.07%Forma y color:SolidPeso molecular:3321.61PD-1/PD-L1-IN-51
PD-1/PD-L1-IN-51 (Compound III-4) is an inhibitor of PD-1/PD-L1 (IC50: hPD-L1 at 2.9 nM). It binds directly to PD-L1, blocking the interaction between PD-1 and PD-L1, and enhancing the release of IFN-γ. Additionally, PD-1/PD-L1-IN-51 exhibits antitumor activity.Forma y color:Odour SolidHuman PD-L1 inhibitor II
CAS:Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Fórmula:C103H151N25O30Forma y color:SolidPeso molecular:2219.486Human PD-L1 inhibitor IV
CAS:PD-L1 inhibitor IV, a polypeptide, competitively blocks hPD-1 with a Kd of 1.38 μM, preventing hPD-1/hPD-L1 interaction.Fórmula:C80H113N25O27Forma y color:SolidPeso molecular:1856.932Eciskafusp alfa
CAS:Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specificPureza:98%Forma y color:SolidPD-1/PD-L1-IN-50
Compound LG-12, known chemically as PD-1/PD-L1-IN-50, is an inhibitor of PD-1/PD-L1. It enhances the secretion of IFN-γ, promotes the activation of CD8+ T cells, and activates T cell-mediated anti-tumor immunity.Forma y color:Odour SolidAnti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.Forma y color:Odour LiquidOpamtistomig
CAS:Opamtistomig is a humanized monoclonal antibody immunoglobulin (H-γ1-scFv-L-κ) dimer targeting human programmed death-ligand 1 (PD-L1), CD274, and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). It is anticipated for use in research on various solid tumors and hematologic malignancies.
Forma y color:LiquidTQB-2858
TQB-2858 is a bifunctional fusion protein composed of an anti-PD-L1 monoclonal antibody fused with the extracellular domain of the TGF-β receptor. It exhibits high affinity for PD-L1, TGF-β1, and TGF-β3, and demonstrates a high target occupancy rate for PD-L1. TQB-2858 can be used in research on osteosarcoma and alveolar soft part sarcoma (ASPS).
Forma y color:Odour LiquidSotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPureza:98%Forma y color:SolidPD-1/PD-L1-IN-48
PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.Forma y color:Odour SolidPD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Fórmula:C22H24N2O2Pureza:99.92%Forma y color:SolidPeso molecular:348.44Ref: TM-T9651
1mg57,00€2mg85,00€5mg127,00€10mg178,00€25mg298,00€50mg405,00€100mg535,00€500mg1.063,00€1mL*10mM (DMSO)140,00€PD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Forma y color:Odour SolidPD-L1/VISTA-IN-2
PD-L1/VISTA-IN-2 (Compound S8) is an orally active dual inhibitor targeting PD-L1 and VISTA, with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. This compound can activate the tumor immune microenvironment, exerting anticancer effects.Fórmula:C22H22N2O3Forma y color:SolidPeso molecular:362.42TPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Fórmula:C109H151F3N34O34S2Forma y color:SolidPeso molecular:2602.69

